NEWS

CNY Fertility has recently partnered with Reprogenetics, a research center focused on providing the procedure of Pre-Implantation Genetic Diagnosis (PGD) to both fertility centers and individuals. But before PGD can begin, an embryo must be produced through methods of In Vitro Fertilization (IVF), which is where we come in. In fact, CNY Fertility is just one of over 200 IVF centers in the US that work with Reprogenetics.
Although Reprogenetics was established in 2000, Dr. Santiago (PGD Program Director), Dr. Jacques Cohen (Scientific Director), and their team have been actively involved in the development of PGD since 1991. Indeed, they were the first to develop PGD tests for certain complication that can arise during pregnancy. To date, Reprogenetics has diagnosed over 20,000 PGD cycles (more than any other PGD laboratory). Their work has, also, been published in more than 150 scientific articles.

The big question: what is PGD?

Pre-implantation genetic diagnosis (PGD) is a “state of the art” alternative to traditional methods of prenatal diagnosis (ultrasound and such). Before PGD, the road to pregnancy begins with IVF treatment, in hopes of producing healthy embryos. Once an embryo is created, PGD allows us to test the embryos for certain conditions before they are placed in a woman’s uterus.

PGD, along with IVF treatment, can now significantly reduce a couple’s risk of giving birth to children with genetic defects such as:

Along with lowering the risk of a genetically mutated pregnancy, PGD can also:

• Increase implantation rates
• Decrease the chance of miscarriage
• Reduce the risk of your baby having a chromosomal disorder
• Better understand the genetic errors that arise in pregnancies of older mothers
• Help you select embryos that are histocompatible (literally, “tissue compatible”) with live siblings. This means that a transplant or blood transfusion from your existing child to your new baby, or vise versa, should be easily accepted.